Experimental triple-agonist weight loss drug retatrutide achieved an average weight reduction of up to 22.6% (55.8 pounds) in patients with severe obesity and cardiovascular disease, according to phase 3 clinical trial results released by manufacturer Eli Lilly. The drug targets receptors for GLP-1, GIP, and glucagon simultaneously to address metabolic conditions.
Phase 3 Results in Obesity and Cardiovascular Disease
The TRIUMPH-3 clinical trial evaluated retatrutide in participants suffering from severe obesity alongside pre-existing cardiovascular conditions. According to the trial data, patients achieved a mean weight loss of up to 55.8 pounds, representing a 22.6% reduction in total body weight. Alongside weight metrics, investigators analyzed cardiovascular safety using major adverse cardiovascular events (MACE) criteria. Statistical evaluations from TRIUMPH-3 reported a hazard ratio of 0.82 for MACE-5 criteria, while the narrower MACE-3 criteria yielded a value of 1.12, according to study disclosures.
Efficacy in Type 2 Diabetes Patients
In addition to the cardiovascular-focused cohort, Eli Lilly reported findings from the TRIUMPH-2 clinical trial examining retatrutide’s efficacy in patients diagnosed with type 2 diabetes. After an 80-week treatment period, participants in this group demonstrated an average body weight reduction of up to 49.6 pounds, or 20.8%, according to trial documentation. Gastrointestinal issues such as nausea, diarrhea, and constipation emerged as the most frequent adverse events during phase 3 testing, though a broad meta-analysis published in late summer 2026 revealed no novel foundational safety concerns.
Comparative Market Analysis and Regulatory Timeline
A meta-analysis published in August 2026, encompassing 38 studies and 25,816 participants, positioned retatrutide’s 48-week average weight reduction of 22.1% against other incretin mimetics and emerging therapies. By comparison, tirzepatide (marketed as Mounjaro) achieved a 19% weight loss over approximately 17 months, while semaglutid (sold as Wegovy and Ozempic) reached roughly 18%. The oral formulation of Wegovy demonstrated a 15.5% reduction after 68 weeks, and newer candidates like amycretin recorded 23.9% at 36 weeks and orforglipron reached 14.7% over the same duration, according to the meta-analysis data. Experts noted that direct head-to-head comparisons remain limited due to varying trial designs.
Eli Lilly stated its intention to submit a Biologics License Application (BLA) for retatrutide to the U.S. Food and Drug Administration (FDA) in the first quarter of 2027. Pending regulatory authorization, the compound remains strictly investigational. Both the manufacturer and health regulators issued warnings against acquiring the drug through illegal grey-market channels, emphasizing that unverified formulations carry substantial health and safety risks.
Worth a look